Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
sulfacetamid 10 % lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing sulfadiazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfabenzamid 3,7 % + sulfacetamid 2,86 % + sulfathiazol 3,42 % vaginalcreme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing sulfabenzamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing sulfadoxine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfamethizole 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfamethoxazole 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfafurazole 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Sulfafurazole 40 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfisoxazol 500 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Demeclocycline hydrochloride 150 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
doxycyclincalcium 25 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely minocycline 10 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely oxytetracycline hydrochloride 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
oxytetracyclin + lidocain 50 mg/ml/2 % injektionsvæske, 2 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
oxytetracyclin 50 mg/ml + lidocain 2 % injektionsvæske, 10 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
oxytetracyclin + lidocain 125 mg/ml/2 % injektionsvæske, 2 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
fosfomycintromethamin 3 g brev |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Methenamine hippurate 1 g oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Methenamine mandelate 100 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Methenamine mandelate 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely methenamine mandelate 1 gram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Methenamine mandelate 300 mg and monobasic sodium phosphate 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
methenaminmandelat 500 mg + natriumhydrogenphosphat 500 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely nitrofurantoin 25 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
vancomycin 1 g pulver til rekonstitution, opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sæt indeholdende bismuthsubsalicylat 262,4 mg + metronidazol 250 mg + tetracyclinhydrochlorid 500 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
polymyxin B-sulfat + bacitracinzink 10.000 enheder/500 enheder øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Acetohydroxamic acid 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely grepafloxacin 200 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Grepafloxacin 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely grepafloxacin 600 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Cinoxacin 250 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely cinoxacin 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Loracarbef 200 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Loracarbef 400 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ethionamide 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Gatifloxacin 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gatifloxacin 200 mg/hætteglas opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
gatifloxacin 400 mg/hætteglas opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Cefdinir 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefepimhydrochlorid 500 mg pulver til injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefepimhydrochlorid 1 g pulver til injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
vancomycinhydrochlorid 500 mg/hætteglas pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
vancomycinhydrochlorid 1 g/glas pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
vancomycinhydrochlorid 1 g pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ceftriaxone (as ceftriaxone sodium) 500 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefriaxonnatrium 10 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefotetandinatrium 10 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefonicidnatrium 1 g/pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
clindamycinphosphat vagitorium a 100 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
kanamycinsulfat 1 g/hætteglas injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Carbenicillin indanyl sodium 382 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
doxycyclinmonohydrat 25 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
doxycyclincalcium 50 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
erythromycinethylsuccinat 400 mg/5 ml pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
erythromycinlactobionat 500 mg pulver til infusionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
erythromycinlactobionat 1 g pulver til infusionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Ciprofloxacin 200mg/100mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely methenamine hippurate 1 gram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefuroximaxetil 250 mg/5 ml pulver til suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Oxacillin (as oxacillin sodium) 1 g powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely oxacillin (as oxacillin sodium) 2 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely nafcillin (as nafcillin sodium) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Nafcillin (as nafcillin sodium) 2 g powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Clindamycin phosphate 300mg/50mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Clindamycin phosphate 600mg/50mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Clindamycin phosphate 900mg/50mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefotetandinatrium 20 mg/ml infusionsvæske, opløsning, hætteglas a 50 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefotetandinatrium 40 mg/ml infusionsvæske, opløsning, hætteglas a 50 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Amoxicillin 125 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
methenaminmandelat 0,5 g tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely doxycycline hyclate 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
doxycyclinhyclat 200 mg pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely sulfacetamide sodium 100 milligram/1 milliliter conventional release eye solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
kanamycinsulfat 1 g/3 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
sulfanilamid 15 % creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefuroximnatrium 7,5 g/100 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefuroximnatrium 7,5 g/pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely paromomycin (as paromomycin sulfate) 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
dicloxacillinnatrium 62,5 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
amoxicillintrihydrat 200 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefuroximnatrium 1,5 g pulver til injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
benzylpenicillin, benzathin 1.200.000 enheder/2 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
chloramphenicolnatriumsuccinat 100 mg/ml pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
mafenidacetat 112 mg creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
mafenidacetat 5 % pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
vancomycinhydrochlorid 10 g opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tobramycinsulfat 60 mg/hætteglas pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
tobramycinsulfat 80 mg/hætteglas, pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ceftizoximnatrium 2 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
ceftizoximnatrium 10 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
clindamycinpalmitathydrochlorid 75 mg/5 ml suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
amoxicillintrihydrat 250 mg tyggetablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
amoxicillintrihydrat 200 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefoperazonnatrium 1 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefoperazonnatrium 2 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
cefoperazonnatrium 10 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|
Product containing precisely trovafloxacin mesilate 200 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Baktericid |
Inferred relationship |
Some |
|